Qualigen Financial Statements From 2010 to 2025

Qualigen Therapeutics Balance Sheet		Trends
Current Value Last Year Historical Average  10 Year Trend Total Assets 4.5 M 4.7 M 9.8 M Slightly volatile Short and Long Term Debt Total 1.4 M 1.5 M 1 M Slightly volatile Total Current Liabilities 1.9 M 2 M 3.4 M Slightly volatile Cash 1.1 M 1.2 M 7.1 M Pretty Stable Non Current Assets Total 1.9 K 2 K 907.8 K Slightly volatile Cash And Short Term Investments 1.1 M 1.2 M 7.5 M Pretty Stable Common Stock Shares Outstanding 343.5 K 361.6 K 1.1 M Slightly volatile Liabilities And Stockholders Equity 4.5 M 4.7 M 9.8 M Slightly volatile Other Current Assets 1.1 M 1.5 M 910.5 K Slightly volatile Total Liabilities 1.9 M 2 M 3.7 M Slightly volatile Total Current Assets 4.5 M 4.7 M 8.9 M Pretty Stable Short Term Debt 820.9 K 1.5 M 700.9 K Slightly volatile Common Stock 68.6 K 65.3 K 26.5 K Slightly volatile Accounts Payable 1.1 M 1.6 M 1.2 M Pretty Stable Common Stock Total Equity 23.34 24.57 8.6 K Slightly volatile Capital Surpluse 68.4 M 91.9 M 62.5 M Slightly volatile Property Plant And Equipment Gross 7.8 M 7.4 M 2.1 M Slightly volatile Property Plant Equipment 1.3 M 2 M 916.2 K Slightly volatile Other Liabilities 491.2 K 467.8 K 163.4 K Slightly volatile Net Receivables 2.4 M 2.3 M 1 M Slightly volatile Inventory 1.1 M 1.8 M 1.2 M Slightly volatile Intangible Assets 7.1 M 6.7 M 1.8 M Slightly volatile Short Term Investments 5.6 M 6.3 M 6.9 M Slightly volatile Long Term Debt 244.6 K 275.2 K 300.1 K Slightly volatile Short and Long Term Debt 1.1 M 1.2 M 1.6 M Slightly volatile Capital Stock 6.1 M 5.8 M 882.9 K Slightly volatile
Qualigen Therapeutics Income Statement		Trends
Current Value Last Year Historical Average  10 Year Trend Depreciation And Amortization 4.9 K 5.2 K 39.1 K Slightly volatile Other Operating Expenses 5.5 M 5.8 M 14 M Slightly volatile Research Development 1.1 M 1.2 M 4.1 M Pretty Stable Cost Of Revenue 7.1 M 6 M 5.6 M Slightly volatile Total Operating Expenses 11.3 M 5.8 M 9.5 M Slightly volatile Interest Income 95.5 K 148.1 K 84.7 K Slightly volatile Selling General Administrative 7 M 4.2 M 6.4 M Pretty Stable Selling And Marketing Expenses 3.8 K 4 K 475.1 K Slightly volatile
Qualigen Therapeutics Cash Flow Statement		Trends
Current Value Last Year Historical Average  10 Year Trend End Period Cash Flow 1.1 M 1.2 M 5.6 M Very volatile Begin Period Cash Flow 381.7 K 401.8 K 6.6 M Pretty Stable Stock Based Compensation 121.7 K 128.1 K 2.2 M Pretty Stable Dividends Paid 74.9 K 78.8 K 1.4 M Pretty Stable
Financial Ratios		Trends
Current Value Last Year Historical Average  10 Year Trend Price To Sales Ratio 29.27 30.81 460 Pretty Stable Dividend Yield 0.0544 0.0518 0.0246 Slightly volatile Days Sales Outstanding 31.03 47.78 44.484 Very volatile Average Payables 1.1 M 1.3 M 1.4 M Slightly volatile Stock Based Compensation To Revenue 0.34 0.19 0.2201 Slightly volatile Capex To Depreciation 0.93 0.98 1.5469 Pretty Stable EV To Sales 29.46 31.01 460 Pretty Stable Inventory Turnover 2.96 3.12 5.3585 Slightly volatile Days Of Inventory On Hand 127 121 77.5537 Slightly volatile Payables Turnover 2.56 2.69 5.4464 Very volatile Sales General And Administrative To Revenue 0.94 1.05 0.7573 Slightly volatile Average Inventory 749.3 K 713.8 K 842.6 K Slightly volatile Research And Ddevelopement To Revenue 0.69 0.9 0.5698 Slightly volatile Capex To Revenue 0.0605 0.0576 0.0376 Slightly volatile Cash Per Share 3.09 3.2485 2.3 K Slightly volatile Days Payables Outstanding 112 179 98.2408 Pretty Stable Intangibles To Total Assets 0.32 0.31 0.1617 Slightly volatile Current Ratio 3.5 2.3335 2.8397 Very volatile Receivables Turnover 7.51 7.91 13.7703 Very volatile Capex Per Share 0.0908 0.0956 8.8597 Pretty Stable Average Receivables 590 K 472.9 K 598.3 K Slightly volatile Revenue Per Share 1.12 1.18 6.7212 Slightly volatile Interest Debt Per Share 2.39 2.5138 225 Slightly volatile Debt To Assets 0.6 0.58 0.3695 Very volatile Operating Cycle 78.56 121 105 Pretty Stable Days Of Payables Outstanding 112 179 98.2408 Pretty Stable Ebt Per Ebit 0.79 1.0679 1.0037 Very volatile Quick Ratio 3.4 2.3335 2.7453 Very volatile Net Income Per E B T 0.81 1.001 0.9936 Slightly volatile Cash Ratio 0.56 0.5851 2.2788 Pretty Stable Days Of Inventory Outstanding 127 121 77.5537 Slightly volatile Days Of Sales Outstanding 31.03 47.78 44.484 Very volatile Fixed Asset Turnover 3.08 3.24 46.7471 Very volatile Debt Ratio 0.6 0.58 0.3695 Very volatile Price Sales Ratio 29.27 30.81 460 Pretty Stable Asset Turnover 2.42 2.3 1.2935 Very volatile
Qualigen Therapeutics Valuation Data		Trends
Current Value Last Year Historical Average  10 Year Trend Market Cap 1.3 M 1.4 M 149.1 M Very volatile Enterprise Value 297.3 K 312.9 K 146.2 M Very volatile

Qualigen Fundamental Market Drivers

Qualigen Upcoming Events

About Qualigen Therapeutics Financial Statements

Pair Trading with Qualigen Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Qualigen Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Qualigen Therapeutics will appreciate offsetting losses from the drop in the long position's value.When determining whether Qualigen Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Qualigen Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Qualigen Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Qualigen Therapeutics Stock:

How To Invest In Qualigen Details

Is Qualigen Stock a good investment? Details

What is Qualigen Therapeutics' Net Worth? Details

Largest Biotechnology Companies View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies View

Altman Z Score Details

Piotroski F Score Details

Beneish M Score Details

Financial Analysis Details

Buy or Sell Advice Details